About this episode
Dr Sridhar Chaganti discusses the current management of post-transplant lymphoproliferative disorder (PTLD), including subtypes, prognostic factors and the current treatment options.
He explores the role of immunotherapy, cytotoxic agents and the emerging field of cellular therapies in this group of patients.
Dr Chaganti is a consultant haematologist at University Hospitals Birmingham NHS Foundation Trust. He has a PhD in cancer studies from the University of Birmingham.
His research interest is Epstein–Barr virus (EBV) and lymphomas. His special interests are in haematologic malignancies, lymphomas and stem cell transplantation.
